Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients

Clinical Transplantation

Volumn 19, Issue 6, 2005, Pages 779-784

  Tierce, J C ^a   Porterfield Baxa, J ^b   Petrilla, A A ^c   Kilburg, A ^c   Ferguson, Ronald M ^b  

^a ValueMedics Research   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Acute rejection; Cost; Dose alteration; Gastrointestinal complications; Mycophenolate mofetil

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; BLOATING; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM ULCER; DRUG DOSE REGIMEN; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RECIPIENT; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VOMITING;

FEMALE; GASTROINTESTINAL DISEASES; GRAFT REJECTION; HOSPITALIZATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; TREATMENT OUTCOME; UNITED STATES;

EID: 28644442483     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2005.00421.x     Document Type: Article

References (18)

1. European Mycophenolate Mofetil Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995: 345: 1321.
2. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996: 61: 1029.
3. Sollinger HW for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate motetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995: 60: 225.
4. Ojo AO, Meier-Kriesche HU, Hanson JA et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000: 69: 2405.
5. Offermann G. Five-year results of renal transplantation on immunosuppressive triple therapy with mycophenolate mofetil. Clin Transplant 2003: 17: 43.
6. Meier-Kriesche HU, Steffen BJ, Hochberg AM et al. Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am J Transplant 2003: 3: 68.
7. Meier-Kriesche HU, Steffen BJ, Hochberg AM et al. Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation 2003: 75: 1341.
8. Meier-Kriesche HU, Ojo AO, Hanson JA et al. Increased impact of acute rejection on chronic allograft failure in recent era. Transplantation 2000: 70: 1098.
9. Behrend M. Adverse GI effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf 2001: 24: 645.
10. Bennett WM. Immunosuppression with mycophenolic acid: one size does not fit all. J Am Soc Nephrol 2003: 14: 2414.
11. Pelletier RP, Akin B, Henry ML et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transpl 2003: 17: 200.
12. Knoll GA, MacDonald I, Khan A et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003: 14: 2381.
13. Hardinger KL, Brennan DC, Lowell J, Schnitzler MA. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transpl Int 2004: 17: 609.
14. Hale MD, Nicholls AJ, Bullingham RE et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998: 64: 672.
15. van Gelder T, Hilbrands LB, Vanrenterghem Y et al. A randomized, double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999: 68: 261.
16. Alomond PS, Matas A, Gillingham K et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993: 55: 752.
17. Sijpkens YW, Doxiadis II, Mallat MJ et al. Early versus late acute rejection episodes in renal transplantation. Transplantation 2003: 75: 204.
18. Schnitzler MA, Hardinger KA, Brennan DC. MMF Dose Modification Following GI Complications in Renal Transplantation. Poster presentation. Boston, MA: ATC, 2004.